Okeiro, a company specializing in precision medicine for transplantation and advanced chronic diseases, today announces a €10 million funding round to accelerate its deployment in France and internationally. This financing round is led by Alven, Red River West, and Forepont Capital Partners.
Technology for point of care and clinical research
Okeiro is pioneering an advanced clinical decision support platform that leverages artificial intelligence to prevent organ failure (kidneys, lungs, heart, and liver). Kidney disease alone affects approximately 850 million people, is one of the leading cause of death worldwide, and accounts for 70% of all organ transplants, with over 250,000 patients remaining on waiting lists for life-saving transplants, highlighting the urgent need for innovative solutions.
At the core of the platform is the groundbreaking iBox algorithm—a clinically validated predictive model, marked as a medical device and qualified as a surrogate endpoint by FDA and EMA—developed in collaboration with their strategic research partner at APHP and INSERM, France’s premier medical research institution. This proprietary technology enables physicians to identify post-transplant complications, revolutionizing patient monitoring and treatment protocols and accelerating clinical trials timelines. Already implemented in leading transplant centers across France and benefiting thousands of patients, Okeiro’s platform has achieved national reimbursement status through the French National Health Insurance, validating both its clinical utility and economic value within established remote monitoring frameworks.
Funding to Accelerate Growth and International Expansion
This funding will enable Okeiro to strengthen its presence in French hospitals where its solution is already deployed, accelerate expansion across Europe (United Kingdom, Germany, Spain), and prepare for entry into the US market this year. Part of the funds will also be used to develop new AI tools to further improve the precision of diagnostics, therapeutic recommendations, and acceleration of clinical research in end-stage chronic disease and transplant patients.
Large-Scale Clinical Study to Validate Clinical Impact
Okeiro is currently conducting a randomized clinical trial across 16 hospital centers in 6 countries (France, Germany, United Kingdom, Austria, Israel, Spain). The objective is to demonstrate the effectiveness of its technology by comparing results between physicians using the platform and a group of physicians applying standard care protocols. Interim results are very positive, and the study will be completed within a few months.
“At Alven we like to back clinical software companies with deep medical-grade IP targeting the US market and aligning industry vertical stakeholders around a new game changing platform. In the wake of what we did with Cardiologs in cardiology a few years ago, we’re thrilled to back Okeiro’s team and help them scale their RPM solution and software business operations to become a major modern player in the chronic diseases category” declares François Meteyer, Partner at Alven.